Copyright Reports & Markets. All rights reserved.

Global New Chemical Entities (NCE) CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of New Chemical Entities (NCE) CDMO by Type
    • 1.3.1 Overview: Global New Chemical Entities (NCE) CDMO Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global New Chemical Entities (NCE) CDMO Consumption Value Market Share by Type in 2025
    • 1.3.3 Peptide NCE
    • 1.3.4 Oligonucleotide NCE
    • 1.3.5 Other
  • 1.4 Global New Chemical Entities (NCE) CDMO Market by Application
    • 1.4.1 Overview: Global New Chemical Entities (NCE) CDMO Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Tumors
    • 1.4.3 Cardiovascular Diseases
    • 1.4.4 Other
  • 1.5 Global New Chemical Entities (NCE) CDMO Market Size & Forecast
  • 1.6 Global New Chemical Entities (NCE) CDMO Market Size and Forecast by Region
    • 1.6.1 Global New Chemical Entities (NCE) CDMO Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global New Chemical Entities (NCE) CDMO Market Size by Region, (2021-2032)
    • 1.6.3 North America New Chemical Entities (NCE) CDMO Market Size and Prospect (2021-2032)
    • 1.6.4 Europe New Chemical Entities (NCE) CDMO Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific New Chemical Entities (NCE) CDMO Market Size and Prospect (2021-2032)
    • 1.6.6 South America New Chemical Entities (NCE) CDMO Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa New Chemical Entities (NCE) CDMO Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 KATSURA CHEMICAL CO., LTD
    • 2.1.1 KATSURA CHEMICAL CO., LTD Details
    • 2.1.2 KATSURA CHEMICAL CO., LTD Major Business
    • 2.1.3 KATSURA CHEMICAL CO., LTD New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.1.4 KATSURA CHEMICAL CO., LTD New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 KATSURA CHEMICAL CO., LTD Recent Developments and Future Plans
  • 2.2 Regis Custom API
    • 2.2.1 Regis Custom API Details
    • 2.2.2 Regis Custom API Major Business
    • 2.2.3 Regis Custom API New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.2.4 Regis Custom API New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Regis Custom API Recent Developments and Future Plans
  • 2.3 Neuland Laboratories Ltd.
    • 2.3.1 Neuland Laboratories Ltd. Details
    • 2.3.2 Neuland Laboratories Ltd. Major Business
    • 2.3.3 Neuland Laboratories Ltd. New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.3.4 Neuland Laboratories Ltd. New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Neuland Laboratories Ltd. Recent Developments and Future Plans
  • 2.4 Aspen API
    • 2.4.1 Aspen API Details
    • 2.4.2 Aspen API Major Business
    • 2.4.3 Aspen API New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.4.4 Aspen API New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Aspen API Recent Developments and Future Plans
  • 2.5 Sai Life Sciences
    • 2.5.1 Sai Life Sciences Details
    • 2.5.2 Sai Life Sciences Major Business
    • 2.5.3 Sai Life Sciences New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.5.4 Sai Life Sciences New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Sai Life Sciences Recent Developments and Future Plans
  • 2.6 Fermion
    • 2.6.1 Fermion Details
    • 2.6.2 Fermion Major Business
    • 2.6.3 Fermion New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.6.4 Fermion New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Fermion Recent Developments and Future Plans
  • 2.7 Dipharma Francis Srl (Dipharma)
    • 2.7.1 Dipharma Francis Srl (Dipharma) Details
    • 2.7.2 Dipharma Francis Srl (Dipharma) Major Business
    • 2.7.3 Dipharma Francis Srl (Dipharma) New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.7.4 Dipharma Francis Srl (Dipharma) New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Dipharma Francis Srl (Dipharma) Recent Developments and Future Plans
  • 2.8 Cohance
    • 2.8.1 Cohance Details
    • 2.8.2 Cohance Major Business
    • 2.8.3 Cohance New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.8.4 Cohance New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Cohance Recent Developments and Future Plans
  • 2.9 Suven Pharma
    • 2.9.1 Suven Pharma Details
    • 2.9.2 Suven Pharma Major Business
    • 2.9.3 Suven Pharma New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.9.4 Suven Pharma New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Suven Pharma Recent Developments and Future Plans
  • 2.10 Syngene
    • 2.10.1 Syngene Details
    • 2.10.2 Syngene Major Business
    • 2.10.3 Syngene New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.10.4 Syngene New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Syngene Recent Developments and Future Plans
  • 2.11 Aarti Pharmalabs Limited (APL)
    • 2.11.1 Aarti Pharmalabs Limited (APL) Details
    • 2.11.2 Aarti Pharmalabs Limited (APL) Major Business
    • 2.11.3 Aarti Pharmalabs Limited (APL) New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.11.4 Aarti Pharmalabs Limited (APL) New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Aarti Pharmalabs Limited (APL) Recent Developments and Future Plans
  • 2.12 Cerbios-Pharma SA
    • 2.12.1 Cerbios-Pharma SA Details
    • 2.12.2 Cerbios-Pharma SA Major Business
    • 2.12.3 Cerbios-Pharma SA New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.12.4 Cerbios-Pharma SA New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Cerbios-Pharma SA Recent Developments and Future Plans
  • 2.13 PharmaBlock Sciences Nanjing Inc
    • 2.13.1 PharmaBlock Sciences Nanjing Inc Details
    • 2.13.2 PharmaBlock Sciences Nanjing Inc Major Business
    • 2.13.3 PharmaBlock Sciences Nanjing Inc New Chemical Entities (NCE) CDMO Product and Solutions
    • 2.13.4 PharmaBlock Sciences Nanjing Inc New Chemical Entities (NCE) CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 PharmaBlock Sciences Nanjing Inc Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global New Chemical Entities (NCE) CDMO Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of New Chemical Entities (NCE) CDMO by Company Revenue
    • 3.2.2 Top 3 New Chemical Entities (NCE) CDMO Players Market Share in 2025
    • 3.2.3 Top 6 New Chemical Entities (NCE) CDMO Players Market Share in 2025
  • 3.3 New Chemical Entities (NCE) CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 New Chemical Entities (NCE) CDMO Market: Region Footprint
    • 3.3.2 New Chemical Entities (NCE) CDMO Market: Company Product Type Footprint
    • 3.3.3 New Chemical Entities (NCE) CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global New Chemical Entities (NCE) CDMO Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global New Chemical Entities (NCE) CDMO Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global New Chemical Entities (NCE) CDMO Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global New Chemical Entities (NCE) CDMO Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America New Chemical Entities (NCE) CDMO Consumption Value by Type (2021-2032)
  • 6.2 North America New Chemical Entities (NCE) CDMO Market Size by Application (2021-2032)
  • 6.3 North America New Chemical Entities (NCE) CDMO Market Size by Country
    • 6.3.1 North America New Chemical Entities (NCE) CDMO Consumption Value by Country (2021-2032)
    • 6.3.2 United States New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 6.3.3 Canada New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe New Chemical Entities (NCE) CDMO Consumption Value by Type (2021-2032)
  • 7.2 Europe New Chemical Entities (NCE) CDMO Consumption Value by Application (2021-2032)
  • 7.3 Europe New Chemical Entities (NCE) CDMO Market Size by Country
    • 7.3.1 Europe New Chemical Entities (NCE) CDMO Consumption Value by Country (2021-2032)
    • 7.3.2 Germany New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 7.3.3 France New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 7.3.5 Russia New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 7.3.6 Italy New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific New Chemical Entities (NCE) CDMO Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific New Chemical Entities (NCE) CDMO Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific New Chemical Entities (NCE) CDMO Market Size by Region
    • 8.3.1 Asia-Pacific New Chemical Entities (NCE) CDMO Consumption Value by Region (2021-2032)
    • 8.3.2 China New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 8.3.3 Japan New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 8.3.5 India New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 8.3.7 Australia New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America New Chemical Entities (NCE) CDMO Consumption Value by Type (2021-2032)
  • 9.2 South America New Chemical Entities (NCE) CDMO Consumption Value by Application (2021-2032)
  • 9.3 South America New Chemical Entities (NCE) CDMO Market Size by Country
    • 9.3.1 South America New Chemical Entities (NCE) CDMO Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa New Chemical Entities (NCE) CDMO Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa New Chemical Entities (NCE) CDMO Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa New Chemical Entities (NCE) CDMO Market Size by Country
    • 10.3.1 Middle East & Africa New Chemical Entities (NCE) CDMO Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)
    • 10.3.4 UAE New Chemical Entities (NCE) CDMO Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 New Chemical Entities (NCE) CDMO Market Drivers
  • 11.2 New Chemical Entities (NCE) CDMO Market Restraints
  • 11.3 New Chemical Entities (NCE) CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 New Chemical Entities (NCE) CDMO Industry Chain
  • 12.2 New Chemical Entities (NCE) CDMO Upstream Analysis
  • 12.3 New Chemical Entities (NCE) CDMO Midstream Analysis
  • 12.4 New Chemical Entities (NCE) CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global New Chemical Entities (NCE) CDMO market size was valued at US$ 3336 million in 2025 and is forecast to a readjusted size of US$ 6908 million by 2032 with a CAGR of 11.1% during review period.
    New Chemical Entities (NCE) refer to new compounds that have not yet been approved for any therapeutic use during the drug development process. These compounds are usually obtained through the synthesis or discovery of new molecules and have new activities or therapeutic potential. NCE is usually the first step in drug development, and after evaluating its safety and effectiveness in clinical trials, it may be applied for marketing. CDMO (Contract Development and Manufacturing Organization) refers to a company that provides drug development and production services, usually working with pharmaceutical companies to help them develop and manufacture NCE. CDMO can provide a range of services from preliminary compound synthesis, process development, to the production of drugs for clinical trials and commercial production. In short, NCE is a newly developed drug ingredient, and CDMO is a service provider that specializes in helping pharmaceutical companies develop and produce NCE.
    This report is a detailed and comprehensive analysis for global New Chemical Entities (NCE) CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global New Chemical Entities (NCE) CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
    Global New Chemical Entities (NCE) CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global New Chemical Entities (NCE) CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global New Chemical Entities (NCE) CDMO market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for New Chemical Entities (NCE) CDMO
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global New Chemical Entities (NCE) CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include KATSURA CHEMICAL CO., LTD, Regis Custom API, Neuland Laboratories Ltd., Aspen API, Sai Life Sciences, Fermion, Dipharma Francis Srl (Dipharma), Cohance, Suven Pharma, Syngene, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    New Chemical Entities (NCE) CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Peptide NCE
    Oligonucleotide NCE
    Other
    Market segment by Application
    Tumors
    Cardiovascular Diseases
    Other
    Market segment by players, this report covers
    KATSURA CHEMICAL CO., LTD
    Regis Custom API
    Neuland Laboratories Ltd.
    Aspen API
    Sai Life Sciences
    Fermion
    Dipharma Francis Srl (Dipharma)
    Cohance
    Suven Pharma
    Syngene
    Aarti Pharmalabs Limited (APL)
    Cerbios-Pharma SA
    PharmaBlock Sciences Nanjing Inc
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe New Chemical Entities (NCE) CDMO product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of New Chemical Entities (NCE) CDMO, with revenue, gross margin, and global market share of New Chemical Entities (NCE) CDMO from 2021 to 2026.
    Chapter 3, the New Chemical Entities (NCE) CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and New Chemical Entities (NCE) CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of New Chemical Entities (NCE) CDMO.
    Chapter 13, to describe New Chemical Entities (NCE) CDMO research findings and conclusion.

    Buy now